What is ALXO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.17B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALXO?

P/E (TTM) is n/a and 52-week range is $1.05 to $2.66 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALXO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALXO?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-2.76B, EPS (TTM) near $-1.14 when available from the market-data feed. Figures are informational and may lag live markets.

Where is ALX Oncology Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 134.6M shares outstanding, ISIN US00166B1052 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

ALX Oncology Holdings Inc

$ALXO

Health Care · Biotechnology

IR Run Scenarios

$1.25

+5.93%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 43 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

Employees

Website

alxoncology.com/

IPO

2020-07-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)